Timeline
MBP134
A monoclonal antibody cocktail developed by Mapp Biopharmaceutical that targets multiple Ebola species including Bundibugyo, showing 100% animal protection up to eight days post-infection; under WHO-sponsored trial pending DRC and Uganda approval.
2 of 2 entries (2 events, 0 interactions)
Filters
#420 May
Demonstrated 100% animal protection up to eight days post-infection and awaited regulatory clearance for human trial
Pandemics and Biosecurity: Ebola drug trial awaits DRC, Uganda nod#420 May